ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Preserflo MicroShunt in refractory glaucoma: multicentre european results with up to three years of follow-up.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Preserflo microshunt outcomes in pigmentary glaucoma: a propensity score-matched comparison with primary open-angle glaucoma.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Preserflo MicroShunt Outcomes in Rare and Refractory Glaucoma Entities Compared with Matched Primary Open-Angle Glaucoma Controls: A Retrospective Exploratory Study.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the real-world 3-year safety and efficacy of the Preserflo MicroShunt with mitomycin-C(MMC) in reducing intraocular pressure(IOP) and medications in patients with inadequately controlled glaucoma.
methodsThis retrospective, multicentre, open-label study included consecutive patients who received the Preserflo MicroShunt implantation with MMC. We included patients with glaucoma (primary open-angle glaucoma (POAG), pseudoexfoliative glaucoma (PXF), pigmentary dispersion glaucoma (PDG), normal-tension glaucoma (NTG), ocular hypertension (OHT), primary angle-closure glaucoma (PACG), uveitic glaucoma and other) inadequately controlled by medical therapy. The primary endpoints were the mean change in IOP and the number of IOP-lowering medications from baseline. Treatment success was defined as achieving IOP ≤ 18 mmHg and a 20% reduction from baseline with (qualified success) or without (complete success) the need for hypotensive medications.
resultsA total of 242 patients had a mean baseline IOP of 25.3 ± 7.2 mmHg, reduced to 13.6 ± 4.7 mmHg at 1 year, 13.5 ± 5.1 mmHg at 2 years, and 13.1 ± 4.6 mmHg at 3 years (p < 0.0001). Medication burden decreased from 3.0 ± 1.0 at baseline to 0.55 ± 0.7 at 1 year, 0.72 ± 0.9 at 2 years, and 0.72 ± 0.9 at 3 years (p < 0.0001). Overall success rates at 1,2 and 3 years were 76.1%, 71.7% and 68.7% respectively. Common adverse events included hyphema (9 eyes), hypotony (5), and choroidal detachment (4). Over three years, the most common interventions included needling (22), surgical revision (29), and tube surgery (8).
conclusionsIn a real-world, multicentre setting, the Preserflo MicroShunt showed sustained IOP reduction and decreased medication use over 3 years, supporting its long-term safety and efficacy.
Indexed as
Identifiers
41521221What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.